Full-length isoform sequencing for resolving the molecular basis of Charcot-Marie-Tooth 2A
Andrew B. StergachisiD, Elizabeth BlueiD, Madelyn A. GillentineiD, Lee-kai WangiD, Ulrike Schwarze, Adriana Estela Sedeño-CortésiD, Jane Ranchalis, Aimee Allworth, Austin E. Bland, Sirisak Chanprasert, Jingheng Chen, Daniel Doherty, Andrew B. FoltaiD, Ian A. GlassiD, Martha J. Horike-PyneiD, Alden HuangiD, Alyna KhaniD, Kathleen A. LeppigiD, Danny E. MilleriD, Ghayda MirzaaiD, Azma Parhin, Wendy H. RaskindiD, Elisabeth A. RosenthaliD, Sam Sheppeard, Samuel D. StrohbehniD, , Fuki Marie HisamaiD
Abstract
ObjectivesTranscript sequencing of patient derived samples has been shown to improve the diagnostic yield for solving cases of likely Mendelian disorders, yet the added benefit of full-length long-read transcript sequencing is largely unexplored. MethodsWe applied short-read and full-length isoform cDNA sequencing and mitochondrial functional studies to a patient-derived fibroblast cell line from an individual with neuropathy that previously lacked a molecular diagnosis. ResultsWe identified an intronic homozygous MFN2 c.600-31T>G variant that disrupts a branch point critical for intron 6 spicing. Full-length long-read isoform cDNA sequencing after treatment with a nonsense-mediated mRNA decay (NMD) inhibitor revealed that this variant creates five distinct altered splicing transcripts. All five altered splicing transcripts have disrupted open reading frames and are subject to NMD. Furthermore, a patient-derived fibroblast line demonstrated abnormal lipid droplet formation, consistent with MFN2 dysfunction. Although correctly spliced full-length MFN2 transcripts are still produced, this branch point variant results in deficient MFN2 protein levels and autosomal recessive Charcot-Marie-Tooth disease, axonal, type 2A (CMT2A). DiscussionThis case highlights the utility of full-length isoform sequencing for characterizing the molecular mechanism of undiagnosed rare diseases and expands our understanding of the genetic basis for CMT2A.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- FWCI
- 0.73
- Field percentile
- top 36%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A cellular assay to determine the fusion capacity of MFN2 variants linked to Charcot-Marie-Tooth type 2A
Chloe Barsa, Julian Perrin, … Manuel Rojo·Scientific ReportsPeer-reviewed·Mar 22, 2025
- Characterization of a novel variant in the HR1 domain of MFN2 in a patient with ataxia, optic atrophy and sensorineural hearing loss
Govinda Sharma, Mashiat Zaman, … Timothy E. Shutt·F1000ResearchPeer-reviewed·Sep 2, 2022
- A deep intronic variant in MME causes autosomal recessive Charcot-Marie-Tooth neuropathy through aberrant splicing
Bianca Rose Grosz, J. Parmar, … Marina L. Kennerson·medRxiv·Apr 22, 2024
- Gene therapy-mediated overexpression of wild-type MFN2 improves Charcot-Marie-Tooth disease type 2A
Marine Tessier, Zeinab Hamzé, … Nathalie Bernard‐Marissal·bioRxiv·Oct 15, 2025
- A novel variant in MFN2 linked to a lethal disorder of neonatal onset
Mashiat Zaman, Cole Chute, … Timothy E. Shutt·medRxiv·Sep 5, 2024
- Characterization of full-length CNBP expanded alleles in myotonic dystrophy type 2 patients by Cas9-mediated enrichment and nanopore sequencing
Massimiliano Alfano, Luca De Antoni, … Marzia Rossato·eLifePeer-reviewed·Aug 26, 2022